Amalgamated Bank Sells 285 Shares of Chemed Co. (NYSE:CHE)

Amalgamated Bank cut its holdings in Chemed Co. (NYSE:CHEGet Rating) by 2.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,317 shares of the company’s stock after selling 285 shares during the period. Amalgamated Bank owned approximately 0.08% of Chemed worth $5,733,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new position in shares of Chemed in the fourth quarter valued at about $32,000. UMB Bank N A MO increased its position in shares of Chemed by 347.1% in the first quarter. UMB Bank N A MO now owns 76 shares of the company’s stock valued at $39,000 after acquiring an additional 59 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Chemed in the first quarter valued at about $46,000. Signaturefd LLC increased its position in shares of Chemed by 69.6% in the first quarter. Signaturefd LLC now owns 95 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in shares of Chemed in the first quarter valued at about $75,000. 90.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada decreased their price objective on shares of Chemed from $592.00 to $541.00 and set an “outperform” rating on the stock in a research report on Monday, August 1st.

Chemed Price Performance

Shares of NYSE CHE opened at $480.29 on Monday. Chemed Co. has a 1 year low of $403.00 and a 1 year high of $539.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.71 and a quick ratio of 0.68. The company’s 50-day moving average is $485.37 and its 200 day moving average is $486.17. The stock has a market capitalization of $7.16 billion, a P/E ratio of 26.71, a P/E/G ratio of 3.61 and a beta of 0.51.

Chemed (NYSE:CHEGet Rating) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $4.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.06. Chemed had a net margin of 12.95% and a return on equity of 44.64%. The company had revenue of $531.29 million for the quarter, compared to analysts’ expectations of $538.07 million. During the same quarter in the previous year, the company earned $4.60 earnings per share. Chemed’s quarterly revenue was down .2% on a year-over-year basis. On average, sell-side analysts expect that Chemed Co. will post 18.72 earnings per share for the current year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 2nd. Investors of record on Monday, August 15th were given a dividend of $0.38 per share. The ex-dividend date of this dividend was Friday, August 12th. This represents a $1.52 annualized dividend and a dividend yield of 0.32%. This is a boost from Chemed’s previous quarterly dividend of $0.36. Chemed’s payout ratio is currently 8.45%.

Insider Activity at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $481.93, for a total transaction of $1,445,790.00. Following the transaction, the chief executive officer now owns 125,185 shares in the company, valued at $60,330,407.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 13th. The shares were sold at an average price of $474.13, for a total value of $948,260.00. Following the sale, the chief executive officer now owns 124,235 shares in the company, valued at $58,903,540.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the company’s stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $481.93, for a total transaction of $1,445,790.00. Following the completion of the sale, the chief executive officer now owns 125,185 shares in the company, valued at approximately $60,330,407.05. The disclosure for this sale can be found here. 4.03% of the stock is owned by corporate insiders.

About Chemed

(Get Rating)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Articles

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEGet Rating).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.